Published in J Immunol on October 15, 1998
Tissue granuloma structure-function in experimental visceral leishmaniasis. Int J Exp Pathol (2001) 1.67
Distinct roles for IL-6 and IL-12p40 in mediating protection against Leishmania donovani and the expansion of IL-10+ CD4+ T cells. Eur J Immunol (2006) 1.44
Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother (2001) 1.39
Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infect Immun (2003) 1.38
Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect Immun (2003) 1.28
Differential immune regulation of activated T cells between cutaneous and mucosal leishmaniasis as a model for pathogenesis. Parasite Immunol (2007) 1.25
Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity. J Virol (2006) 1.25
CTLA-4 blockade enhances the immune response induced by mycobacterial infection but does not lead to increased protection. Infect Immun (1999) 1.23
Early gene expression of NK cell-activating chemokines in mice resistant to Leishmania major. Infect Immun (1999) 1.21
Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells. J Exp Med (2001) 1.17
Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection. Am J Pathol (2004) 1.17
CD8 T cell exhaustion in human visceral leishmaniasis. J Infect Dis (2013) 1.06
Foxp3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients. PLoS Negl Trop Dis (2011) 1.05
Mechanisms of immune evasion in leishmaniasis. Adv Appl Microbiol (2013) 1.04
Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Infect Immun (2003) 1.02
An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci U S A (2009) 1.01
T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant? Front Immunol (2012) 0.98
The Schistosoma mansoni hepatic egg granuloma provides a favorable microenvironment for sustained growth of Leishmania donovani. Am J Pathol (2006) 0.95
VCAM-1 and VLA-4 modulate dendritic cell IL-12p40 production in experimental visceral leishmaniasis. PLoS Pathog (2008) 0.94
Regulation of immunity during visceral Leishmania infection. Parasit Vectors (2016) 0.92
Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice. J Clin Invest (2010) 0.92
Immunoregulation in human American leishmaniasis: balancing pathology and protection. Parasite Immunol (2014) 0.90
Interleukin-4-independent acceleration of cutaneous leishmaniasis in susceptible BALB/c mice following treatment with anti-CTLA4 antibody. Infect Immun (1999) 0.89
CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response. Infect Immun (2000) 0.89
Immune regulation during chronic visceral leishmaniasis. PLoS Negl Trop Dis (2014) 0.88
CD4+ CD25+ Foxp3- T-regulatory cells produce both gamma interferon and interleukin-10 during acute severe murine spotted fever rickettsiosis. Infect Immun (2009) 0.88
Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. Infect Immun (2007) 0.86
Lessons from other diseases: granulomatous inflammation in leishmaniasis. Semin Immunopathol (2015) 0.85
Differential Regulation of the Immune Response in the Spleen and Liver of Mice Infected with Leishmania donovani. J Trop Med (2011) 0.84
Cytotoxic T lymphocyte antigen costimulation influences T-cell activation in response to Cryptococcus neoformans. Infect Immun (2001) 0.78
PD-1 modulates steady-state and infection-induced IL-10 production in vivo. Eur J Immunol (2013) 0.77
Combined Immune Therapy for the Treatment of Visceral Leishmaniasis. PLoS Negl Trop Dis (2016) 0.76
Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse. Clin Dev Immunol (2013) 0.76
CD4+ Recent Thymic Emigrants Are Recruited into Granulomas during Leishmania donovani Infection but Have Limited Capacity for Cytokine Production. PLoS One (2016) 0.75
The Cytotoxic T Lymphocyte Antigen-4 +49A/G Single Nucleotide Polymorphism Association With Visceral Leishmaniasis. Jundishapur J Microbiol (2014) 0.75
Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol (1998) 1.89
B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology. J Immunol (2000) 1.73
Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol (2000) 1.72
Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur J Immunol (1998) 1.65
Nonphagocytic dendritic cells are effective accessory cells for anti-mycobacterial responses in vitro. J Immunol (1985) 1.42
Organ-specific immune responses associated with infectious disease. Immunol Today (2000) 1.39
Destruction of follicular dendritic cells during chronic visceral leishmaniasis. J Immunol (1997) 1.36
Regulation of macrophage accessory cell activity by mycobacteria. II. In vitro inhibition of Ia expression by Mycobacterium microti. Clin Exp Immunol (1986) 1.25
A modified colorimetric assay of macrophage activation for intracellular cytotoxicity against Leishmania parasites. J Immunol Methods (1990) 1.21
The biochemistry and cell biology of antigen processing. Immunol Rev (1988) 1.18
Immunoregulatory pathways in murine leishmaniasis: different regulatory control during Leishmania mexicana mexicana and Leishmania major infections. Clin Exp Immunol (1985) 1.13
Bromelain, from pineapple stems, proteolytically blocks activation of extracellular regulated kinase-2 in T cells. J Immunol (1999) 1.09
An in vivo analysis of cytokine production during Leishmania donovani infection in scid mice. Exp Parasitol (1996) 1.08
Leishmania donovani infection initiates T cell-independent chemokine responses, which are subsequently amplified in a T cell-dependent manner. Eur J Immunol (1999) 1.08
Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine (2007) 1.06
IgG subclass responses in a longitudinal study of canine visceral leishmaniasis. Vet Immunol Immunopathol (2003) 1.06
Leishmania donovani-infected macrophages: characterization of the parasitophorous vacuole and potential role of this organelle in antigen presentation. J Cell Sci (1994) 1.05
Tissue cytokine responses in canine visceral leishmaniasis. J Infect Dis (2001) 1.03
An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci U S A (2009) 1.01
Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines. Trans R Soc Trop Med Hyg (2001) 0.99
Enhanced hematopoietic activity accompanies parasite expansion in the spleen and bone marrow of mice infected with Leishmania donovani. Infect Immun (2000) 0.97
Pulmonary dendritic cells and alveolar macrophages are regulated by gammadelta T cells during the resolution of S. pneumoniae-induced inflammation. J Pathol (2007) 0.96
Leishmania donovani infection of bone marrow stromal macrophages selectively enhances myelopoiesis, by a mechanism involving GM-CSF and TNF-alpha. Blood (2000) 0.95
Role of Lsh in regulating macrophage priming/activation. Res Immunol (1989) 0.94
CD95 is required for the early control of parasite burden in the liver of Leishmania donovani-infected mice. Eur J Immunol (2001) 0.93
C-reactive protein binds to a novel ligand on Leishmania donovani and increases uptake into human macrophages. J Immunol (1996) 0.92
Antigen presentation by dendritic cells provides optimal stimulation for the production of interleukin (IL) 2, IL 4 and interferon-gamma by allogeneic T cells. Eur J Immunol (1991) 0.91
B7-2 blockade enhances T cell responses to Leishmania donovani. J Immunol (1997) 0.90
Acquisition of cell-mediated immunity to Leishmania. I. Primary T-cell activation detected by IL-2 receptor expression. Immunology (1987) 0.89
Regulation of macrophage accessory cell activity by mycobacteria. I. Ia expression in normal and irradiated mice infected with Mycobacterium microti. Clin Exp Immunol (1986) 0.89
Recombinant interleukin-1 alpha augments granuloma formation and cytokine production but not parasite clearance in mice infected with Leishmania donovani. Infect Immun (1992) 0.88
Epitope cleavage by Leishmania endopeptidase(s) limits the efficiency of the exogenous pathway of major histocompatibility complex class I-associated antigen presentation. Eur J Immunol (1997) 0.87
The interaction of beta 2 glycoprotein-I and heparin and its effect on beta 2 glycoprotein-I antiphospholipid antibody cofactor function in plasma. Thromb Haemost (1994) 0.86
The effect of parasitization by Leishmania mexicana mexicana on macrophage function in vitro. Acta Trop (1983) 0.84
Presentation of Leishmania donovani promastigotes occurs via a brefeldin A-sensitive pathway. Eur J Immunol (1991) 0.80
Pathways of macrophage activation and innate immunity. Immunol Lett (1994) 0.80
Teaching terminal care. Br Med J (Clin Res Ed) (1985) 0.79
Hypercalcaemia in advanced malignancy. Lancet (1985) 0.76
Resistance induced by drug abbreviated Schistosoma mansoni infections: treatment with the drug Ro11-3128 leads to enhanced antigen presentation. Immunology (1994) 0.75
Parasites and the immune system: a perspective from down under. Parasite Immunol (2010) 0.75